Infective Endocarditis After Transcatheter versus Surgical Aortic Valve Replacement.
Infective endocarditis
SAVR
TAVR
heart surgery
prognosis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
01
05
2023
revised:
27
07
2023
accepted:
04
08
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
Scarce data are available comparing infective endocarditis (IE) following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). This study aimed to compare the clinical presentation, microbiological profile, management, and outcomes of IE after SAVR vs. TAVR. Data were collected from the "Infectious Endocarditis after TAVR International" (enrollment from 2005 to 2020) and the "International Collaboration on Endocarditis" enrollment from 2000 to 2012) registries. Only patients with an IE affecting the aortic valve prosthesis were included. A 1:1 paired matching approach was used to compare patients with TAVR and SAVR. A total of 1688 patients were included. Of them, 602 (35.7%) had a surgical bioprosthesis (SB), 666 (39.5%) a mechanical prosthesis, 70 (4.2%) a homograft, and 350 (20.7%) a transcatheter heart valve. In the SAVR vs. TAVR matched population, the rate of new moderate or severe aortic regurgitation was higher in the SB group (43.4% vs. 13.4%, p < 0.001), and fewer vegetations were diagnosed in the SB group (62.5% vs. 82%, p < 0.001). Patients with a SB had a higher rate of perivalvular extension (47.9% vs.27%, p < 0.001) and Staphylococcus Aureus was less common in this group (13.4% vs. 22%, p = 0.033). Despite a higher rate of surgery in patients with SB (44.4% vs. 26.8%, p < 0.001), 1-year mortality was similar (SB: 46.5%, TAVR: 44.8%, log-rank p = 0.697). Clinical presentation, type of causative microorganism and treatment differed between patients with an IE located on SB compared to TAVR. Despite these differences, both groups exhibited high and similar mortality at 1-year follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Scarce data are available comparing infective endocarditis (IE) following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). This study aimed to compare the clinical presentation, microbiological profile, management, and outcomes of IE after SAVR vs. TAVR.
METHODS
METHODS
Data were collected from the "Infectious Endocarditis after TAVR International" (enrollment from 2005 to 2020) and the "International Collaboration on Endocarditis" enrollment from 2000 to 2012) registries. Only patients with an IE affecting the aortic valve prosthesis were included. A 1:1 paired matching approach was used to compare patients with TAVR and SAVR.
RESULTS
RESULTS
A total of 1688 patients were included. Of them, 602 (35.7%) had a surgical bioprosthesis (SB), 666 (39.5%) a mechanical prosthesis, 70 (4.2%) a homograft, and 350 (20.7%) a transcatheter heart valve. In the SAVR vs. TAVR matched population, the rate of new moderate or severe aortic regurgitation was higher in the SB group (43.4% vs. 13.4%, p < 0.001), and fewer vegetations were diagnosed in the SB group (62.5% vs. 82%, p < 0.001). Patients with a SB had a higher rate of perivalvular extension (47.9% vs.27%, p < 0.001) and Staphylococcus Aureus was less common in this group (13.4% vs. 22%, p = 0.033). Despite a higher rate of surgery in patients with SB (44.4% vs. 26.8%, p < 0.001), 1-year mortality was similar (SB: 46.5%, TAVR: 44.8%, log-rank p = 0.697).
CONCLUSIONS
CONCLUSIONS
Clinical presentation, type of causative microorganism and treatment differed between patients with an IE located on SB compared to TAVR. Despite these differences, both groups exhibited high and similar mortality at 1-year follow-up.
Identifiants
pubmed: 37552784
pii: 7239252
doi: 10.1093/cid/ciad464
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.